These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma. de Souza Braga M; Chaves KB; Chammas R; Schor N; Bellini MH Biomed Pharmacother; 2012 Jun; 66(4):237-41. PubMed ID: 22560459 [TBL] [Abstract][Full Text] [Related]
4. Involvement of the NF-кB/p50/Bcl-3 complex in response to antiangiogenic therapy in a mouse model of metastatic renal cell carcinoma. de Souza Braga M; da Silva Paiva KB; Foguer K; Barbosa Chaves KC; de Sá Lima L; Scavone C; Bellini MH Biomed Pharmacother; 2014 Sep; 68(7):873-9. PubMed ID: 25113400 [TBL] [Abstract][Full Text] [Related]
5. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model. Chaves KC; Peron JP; Chammas R; Turaça LT; Pesquero JB; Braga MS; Foguer K; Schor N; Bellini MH Cancer Gene Ther; 2012 Aug; 19(8):558-65. PubMed ID: 22699868 [TBL] [Abstract][Full Text] [Related]
7. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. Rocha FG; Chaves KC; Chammas R; Peron JP; Rizzo LV; Schor N; Bellini MH Cancer Immunol Immunother; 2010 Sep; 59(9):1357-65. PubMed ID: 20490489 [TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors. Guan X; Liu Z; Zhang J; Jin X Adv Clin Exp Med; 2018 Jul; 27(7):947-953. PubMed ID: 29905412 [TBL] [Abstract][Full Text] [Related]
9. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783 [TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249 [No Abstract] [Full Text] [Related]
12. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209 [TBL] [Abstract][Full Text] [Related]
13. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314 [TBL] [Abstract][Full Text] [Related]
14. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969 [TBL] [Abstract][Full Text] [Related]
15. CXCL17-derived CD11b Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260 [TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. Flörcken A; Takvorian A; Singh A; Gerhardt A; Ostendorf BN; Dörken B; Pezzutto A; Westermann J Immunol Lett; 2015 Dec; 168(2):260-7. PubMed ID: 26462434 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. Wang HF; Ning F; Liu ZC; Wu L; Li ZQ; Qi YF; Zhang G; Wang HS; Cai SH; Du J Cancer Immunol Immunother; 2017 Mar; 66(3):355-366. PubMed ID: 27915371 [TBL] [Abstract][Full Text] [Related]
18. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624 [TBL] [Abstract][Full Text] [Related]
19. Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo. Hegde VL; Singh UP; Nagarkatti PS; Nagarkatti M J Immunol; 2015 Jun; 194(11):5211-22. PubMed ID: 25917103 [TBL] [Abstract][Full Text] [Related]
20. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma. Zhao Q; Guo J; Wang G; Chu Y; Hu X Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]